Last update 20 Mar 2025

Plasminogen(Omnio AB)

Overview

Basic Info

Drug Type
Enzyme
Synonyms-
Target
PLG
Action
modulators
Mechanism
PLG modulators(Plasminogen modulators)
Therapeutic Areas
Nervous System DiseasesCardiovascular DiseasesEndocrinology and Metabolic Disease+ [2]
Active Indication
Diabetic FootEar Diseases
Inactive Indication
Plasminogen Deficiency, Type I
Originator Organization
ProMetic Biotherapeutics Ltd.
Active Organization
Omnio ABOmnio ABLiminal BioSciences, Inc.Liminal BioSciences, Inc.
Inactive Organization
ProMetic Biotherapeutics Ltd.
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Related

2
Clinical Trials associated with Plasminogen(Omnio AB)
NCT02690714
/ CompletedPhase 2/3
A Phase 2/3, Open-Label, Repeat-Dose Study of the Pharmacokinetics, Efficacy, and Safety of Prometic Plasminogen Intravenous Infusion in Subjects With Hypoplasminogenemia
NCT02312180
/ CompletedPhase 1
A Phase 1, Dose Escalation, and Pharmacokinetic Study of ProMetic Plasminogen Administered as Intravenous Infusion in Adults and Children With Hypoplasminogenemia
100 Clinical Results associated with Plasminogen(Omnio AB)
Login to view more data
100 Translational Medicine associated with Plasminogen(Omnio AB)
Login to view more data
100 Patents (Medical) associated with Plasminogen(Omnio AB)
Login to view more data
100 Deals associated with Plasminogen(Omnio AB)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetic FootPhase 2-
Omnio ABOmnio AB
-
Diabetic FootPhase 2-
Liminal BioSciences, Inc.Liminal BioSciences, Inc.
-
Ear DiseasesPhase 2-
Liminal BioSciences, Inc.Liminal BioSciences, Inc.
-
Ear DiseasesPhase 2-
Omnio ABOmnio AB
-
Plasminogen Deficiency, Type IDiscovery
United States
ProMetic Biotherapeutics Ltd.
01 Dec 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT02690714 (CTgov)
Phase 2/3
Congenital Plasminogen Deficiency
15
bdawjefsnb(ejswsvtehv) = uhxpjkzixm lssdmuetko (nzqtoifzij, amwkmdesoe - pclimjvkbq)
View more
-
19 Apr 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free